Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia

Dystonia Clinical Trial

— DYSCHOL  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02727361
• Other study ID #: CHUBX2014/20
• Status: Completed
• Phase: N/A
• Start date: January 2016
• Est. completion date: March 1, 2018

Study information

• Verified date: February 2019
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dystonia is defined as a syndrome of sustained muscle contractions resulting in repetitive movements and abnormal postures. DYT1 is the most common form of genetic dystonia, but the link between genomic mutations and phenotypic expression remains largely unknown. Furthermore, secondary forms of dystonia have highlighted the role of the basal ganglia, particularly the putamen in the pathophysiology of the disease. Experimental results in a genetic model of dystonia in rodents suggest that cholinergic inter-neurons (ACh-I) of the putamen play a critical role in the pathological process of plasticity in the cortico-striatal synapse. However, these results have not been demonstrated in humans.

Description:

The purpose of this study is to demonstrate that the phenotype of dystonia is associated with the degree of striatal ACh-I alterations.

In this molecular imaging study, the investigators will directly test this hypothesis using a PET radiotracer of the vesicular acetylcholine transporter (VAT). Their goal is to explore the relationships between cholinergic dysfunction and clinical disease expression and the associated morphological and functional alterations. The experimental protocol will also include multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 1, 2018
• Est. primary completion date: March 1, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Man or woman 18 to 75 years, with health insurance European health insurance card (for resident patients in EU), insurance by bilateral social security agreement signed between his country and France (for resident patients outside the EU)

• Diagnosis of dystonia DYT1 confirmed by molecular biology (TORSINE- A gene mutation)

• Patient who stopped his anticholinergic treatment 48 hours before imaging

Exclusion Criteria:

• Patients who underwent surgery for deep brain stimulation or under cholinergic treatment.

• Presence of a counter-indication for MRI

• Presence of a counter-indication for TEP Scan with [18F]-FEOBV

• Woman premenopausal without effective ongoing contraception (intrauterine device or combined hormonal)

• Patient who underwent a PET examination in the previous month

• Presence of any health problem preventing travel to the imaging service of the University Hospital

• Being under the legal guardianship of another person or being unable to provide consent to participate

• Pregnant or breastfeeding woman

Related Conditions & MeSH terms

• Dystonia
• Dystonic Disorders

Intervention

Radiation:
• PET (Positron Emission Tomography) imaging
Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.

Other:
• MRI : Magnetic Resonance Imaging
Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Binding potential	Image (PET) of the intensity of fixation of Cholinergic tracer (Binding potential)	Inclusion (V0)